LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vaccine Against Nicotine Addiction

By Biotechdaily staff writers
Posted on 28 May 2003
Scientists have created a vaccine against nicotine addiction that has been shown effective in laboratory models. The structure and design are described in the June 18, 2003, issue of the Journal of the American Chemical Society.

The scientists used an "immunopharmacotherapy” approach to design a drug that stimulates the immune system to clear the nicotine from the system. To do this, they selected a chemical that resembles nicotine and used it to induce an active immune response. In this immune response, the body produces antibodies against nicotine that can neutralize it in the bloodstream. If a smoker is given the vaccine and later smokes a cigarette, the antibodies will clear the nicotine from the system before it reaches the smoker's brain.

The vaccine, when approved, could be given to people undergoing smoking cessation programs to aid their recovery. The scientists used the same approach to design a vaccine against cocaine, currently in clinical trials.

"These new vaccines greatly suppress the reinforcing aspects of a drug,” said principal investigator Kim D. Janda, Ph.D., an investigator in The Skaggs Institute for Chemical Biology at The Scripps Institute (La Jolla, CA, USA). "This could be a general method for vaccine development for drugs of abuse.”




Related Links:
Scripps

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gastrointestinal Panel
Xpert® GI Panel
Portable POCT Blood Gas Analyzer
BD100

Latest BioResearch News

Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
28 May 2003  |   BioResearch

Population-Scale Proteomics Study Identifies New Genetic-Protein Links
28 May 2003  |   BioResearch

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
28 May 2003  |   BioResearch